The phase 2 trial involved 560 healthy volunteers, and results show that the vaccine was able to prompt a response to COVID-19 within 14 days of the first dose. It produces a similar immune response among adults of all ages.
People over the age of 70 are at a high risk of developing severe illness if they contract COVID-19. The vaccine is now in phase 3 trials and is being tested to see if it can protect the elderly and people with underlying health conditions from COVID-19, The Hill reported.
Phase 3 trial results should be known by Christmas, AstraZeneca and the University of Oxford said.
Find the full study results here.
More articles on pharmacy:
3 key vaccine production challenges drugmakers are facing
What Amazon’s online pharmacy announcement did to CVS, Walgreens and Rite Aid stock
Every state will have COVID-19 vaccine within 24 hours of FDA’s OK, federal officials say
